Dextromethorphan/bupropion vs Solriamfetol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: Dopamine/norepinephrine transporter · full Major Depressive Disorder pipeline

Dextromethorphan/bupropion · Auvelity

Marketed by Axsome Therapeutics

Approved in Major Depressive Disordersmall molecule combination
Partial signal

NCT02741791 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 312 participants, using change in the clinical MADRS depression score as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change in MADRS Total Score From Baseline to Week 6 (6 weeks): Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862) (met)

Result source: NCT04019704

Solriamfetol · Sunosi

Marketed by Axsome Therapeutics and partners

Phase 3 in Major Depressive Disordersmall molecule
Partial signal

NCT06360419 · Phase 3 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2028 · NCT07484217 (registry estimate)

Reported efficacy

Montgomery-Åsberg Depression Rating Scale (MADRS) (6 weeks); Incidence of treatment-emergent adverse events (6 weeks): In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. (missed)

Result source: NCT06360419

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDextromethorphan/​bupropionSolriamfetol
MADRS, change (acute)15.9 vs 12.0+3.9 vs placebowk 6 · n 156NCT04019704
3 other results
  • 13.7 vs 8.8 wk 6 · n 43 · Phase 2 · primary NCT03595579
  • 17.2 vs 12.1 wk 6 · n 43 · Phase 2 · secondary NCT03595579
  • -11.6 vs -9.4 wk 6 · Phase 3 · primary NCT02741791
—Not posted · NCT06360419
CGI-S, change (acute)—Not posted · NCT02741791—Not posted · NCT06360419
MADRS response—Not posted · NCT02741791—Not posted · NCT06360419
MADRS remission—Not posted · NCT02741791—Not posted · NCT06360419
Relapse (% of patients)—Not posted · NCT02741791—Not posted · NCT06360419

MADRS, change (acute)

Dextromethorphan/​bupropion
15.9 vs 12.0+3.9 vs placebowk 6 · n 156NCT04019704
3 other results
  • 13.7 vs 8.8 wk 6 · n 43 · Phase 2 · primary NCT03595579
  • 17.2 vs 12.1 wk 6 · n 43 · Phase 2 · secondary NCT03595579
  • -11.6 vs -9.4 wk 6 · Phase 3 · primary NCT02741791
Solriamfetol
—Not posted · NCT06360419

CGI-S, change (acute)

Dextromethorphan/​bupropion
—Not posted · NCT02741791
Solriamfetol
—Not posted · NCT06360419

MADRS response

Dextromethorphan/​bupropion
—Not posted · NCT02741791
Solriamfetol
—Not posted · NCT06360419

MADRS remission

Dextromethorphan/​bupropion
—Not posted · NCT02741791
Solriamfetol
—Not posted · NCT06360419

Relapse (% of patients)

Dextromethorphan/​bupropion
—Not posted · NCT02741791
Solriamfetol
—Not posted · NCT06360419
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Solriamfetol
In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. NCT06360419 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dextromethorphan/bupropion: 3 of 4 rows · Solriamfetol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDextromethorphan/​bupropion
Dropout rate
24.5%a
NCT04019704 · Phase 3
show 2 more results
20.8%
NCT03595579 · Phase 2
93.9%
NCT04039022 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT04019704 · Phase 3
show 2 more results
—
NCT03595579 · Phase 2
—
NCT04039022 · Phase 3 · registry result, not featured evidence
Serious AEs
0.6%a
NCT04019704 · Phase 3
show 2 more results
0%
NCT03595579 · Phase 2
2.4%
NCT04039022 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
all others, occurring in <5% of subjects 29% (placebo 26.2%)
dizziness 16% (placebo 6.1%)
nausea 13% (placebo 8.5%)
NCT04019704 · Phase 3
show 2 more results
dizziness 20.8%
nausea 16.7%
anxiety 10.4%
NCT03595579 · Phase 2
dizziness 12.7%
nausea 11.9%
headache 8.8%
NCT04039022 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dextromethorphan/bupropion

MADRS 15.91 vs 12.04 placebo score @ 6wk
absolute change · score
NCT04019704 · Phase 3
show 3 more results
13.7 vs 8.8 Bupropion score @ 6wk
NCT03595579 · Phase 2
17.2 vs 12.1 Bupropion score @ 6wk
NCT03595579 · Phase 2
-11.6 vs -9.4 bupropion (active comparator) score @ 6wk
NCT02741791 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dextromethorphan/bupropion's landscape · Solriamfetol's landscape